Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttles

被引:18
作者
Chattopadhyay, Saket [1 ]
Ely, Abdullah [1 ]
Bloom, Kristie [1 ]
Weinberg, Marc S. [1 ]
Arbuthnot, Patrick [1 ]
机构
[1] Univ Witwatersrand, Sch Med, Antiviral Gene Therapy Res Unit, ZA-2050 Johannesburg, Gauteng, South Africa
基金
新加坡国家研究基金会;
关键词
RNA interference; Hepatitis B virus; Anti-HBV micro-RNA; Linear expression cassette; IN-VIVO; ADENOVIRUS TYPE-5; HAIRPIN RNA; INTERFERENCE; SIRNAS; CELLS;
D O I
10.1016/j.bbrc.2009.09.004
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RNA interference (RNAi) may be harnessed to inhibit viral gene expression and this approach is being developed to counter chronic infection with hepatitis B virus (HBV). Compared to synthetic RNAi activators, DNA expression cassettes that generate silencing sequences have advantages of sustained efficacy and ease of propagation in plasmid DNA (pDNA), However, the large size of pDNAs and inclusion of sequences conferring antibiotic resistance and immunostimulation limit delivery efficiency and safety. To develop use of alternative DNA templates that may be applied for therapeutic gene silencing, we assessed the usefulness of PCR-generated linear expression cassettes that produce anti-HBV micro-RNA (miR) shuttles. We found that silencing of HBV markers of replication was efficient (>75%) in cell culture and in vivo. miR shuttles were processed to form anti-HBV guide strands and there was no evidence of induction of the interferon response. Modification of terminal sequences to include flanking human adenoviral type-5 inverted terminal repeats was easily achieved and did not compromise silencing efficacy. These linear DNA sequences should have utility in the development of gene silencing applications where modifications of terminal elements with elimination of potentially harmful and non-essential sequences are required. (C) 2009 Elsevier Inc. All rights reserved.
引用
收藏
页码:484 / 489
页数:6
相关论文
共 20 条
[1]   Opportunities for treating chronic hepatitis B and C virus infection using RNA interference [J].
Arbuthnot, P. ;
Longshaw, V. ;
Naidoo, T. ;
Weinberg, M. S. .
JOURNAL OF VIRAL HEPATITIS, 2007, 14 (07) :447-459
[2]   Hepatic Delivery of RNA Interference Activators for Therapeutic Application [J].
Arbuthnot, Patrick ;
Ely, Abdullah ;
Weinberg, Marc S. .
CURRENT GENE THERAPY, 2009, 9 (02) :91-103
[3]   Effective inhibition of HBV replication in vivo by anti-HBx short hairpin RNAs [J].
Carmona, S ;
Ely, A ;
Crowther, C ;
Moolla, N ;
Salazar, FH ;
Marion, PL ;
Ferry, N ;
Weinberg, MS ;
Arbuthnot, P .
MOLECULAR THERAPY, 2006, 13 (02) :411-421
[4]   Targeting cellular genes with PCR cassettes expressing short interfering RNAs [J].
Castanotto, D ;
Scherer, L .
RNA INTERFERENCE, 2005, 392 :173-+
[5]   THE SEQUENCE OF THE GENOME OF ADENOVIRUS TYPE-5 AND ITS COMPARISON WITH THE GENOME OF ADENOVIRUS TYPE-2 [J].
CHROBOCZEK, J ;
BIEBER, F ;
JACROT, B .
VIROLOGY, 1992, 186 (01) :280-285
[6]  
CROWTHER C, 2008, HUM GENE THER
[7]   The silent treatment: siRNAs as small molecule drugs [J].
Dykxhoorn, DM ;
Palliser, D ;
Lieberman, J .
GENE THERAPY, 2006, 13 (06) :541-552
[8]   Efficient silencing of gene expression with modular trimeric Pol II expression cassettes comprising microRNA shuttles [J].
Ely, Abdullah ;
Naidoo, Tanusha ;
Arbuthnot, Patrick .
NUCLEIC ACIDS RESEARCH, 2009, 37 (13)
[9]   Progress and Prospects: The design and production of plasmid vectors [J].
Gill, D. R. ;
Pringle, I. A. ;
Hyde, S. C. .
GENE THERAPY, 2009, 16 (02) :165-171
[10]   REDUNDANT ELEMENTS IN THE ADENOVIRUS TYPE-5 INVERTED TERMINAL REPEAT PROMOTE BIDIRECTIONAL TRANSCRIPTION INVITRO AND ARE IMPORTANT FOR VIRUS GROWTH-INVIVO [J].
HATFIELD, L ;
HEARING, P .
VIROLOGY, 1991, 184 (01) :265-276